Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA,
Curr Atheroscler Rep. 2015 Jan;17(1):473. doi: 10.1007/s11883-014-0473-6.
Familial hypercholesterolemia (FH), characterized by congenitally elevated low-density lipoprotein cholesterol levels, is estimated to affect 20 million people worldwide. In patients with heterozygous FH, coronary artery disease manifests in about half of men by age 50 and one third of women by age 60, while homozygous FH patients often suffer coronary events in the first or second decade of life. Early diagnosis and aggressive treatment are paramount. However, many FH patients remain undiagnosed and/or inadequately treated. There is a considerable need for more effective screening and diagnosis of FH in the United States. Our objective herein is to provide concise overviews of how to screen for and diagnose FH and summarize international consensus recommendations for managing adults and children with available treatments.
家族性高胆固醇血症(FH)的特征是先天性低密度脂蛋白胆固醇水平升高,据估计,全世界有 2000 万人受其影响。在杂合子 FH 患者中,约一半的男性在 50 岁前、三分之一的女性在 60 岁前会出现冠状动脉疾病,而纯合子 FH 患者通常在生命的第一个或第二个十年就会出现冠状动脉事件。早期诊断和积极治疗至关重要。然而,许多 FH 患者仍未被诊断和/或治疗不足。美国迫切需要更有效的 FH 筛查和诊断方法。我们的目的是提供如何筛查和诊断 FH 的简明概述,并总结国际共识建议,以管理有可用治疗方法的成人和儿童。